I read with interest the article on ocular motility changes after subtenon carboplatin chemotherapy for retinoblastoma.1 It is important that complications of this technique be reported so that physicians worldwide can assess the relative risks and benefits of the procedure. The article is encouraging in that 12 advanced eyes were treated with this technique, and the authors reported no active tumor in 8 of the 12 eyes. This is a wonderful affirmation of the success of this local approach in eyes with retinoblastoma.
Abramson DH. Periocular Chemotherapy for Retinoblastoma: Success With Problems?. Arch Ophthalmol. 2005;123(1):128-129. doi:10.1001/archopht.123.1.128-b